KR102321172B1 - 염증성 질환에서 il-18 결합 단백질(il-18bp) - Google Patents
염증성 질환에서 il-18 결합 단백질(il-18bp) Download PDFInfo
- Publication number
- KR102321172B1 KR102321172B1 KR1020167008846A KR20167008846A KR102321172B1 KR 102321172 B1 KR102321172 B1 KR 102321172B1 KR 1020167008846 A KR1020167008846 A KR 1020167008846A KR 20167008846 A KR20167008846 A KR 20167008846A KR 102321172 B1 KR102321172 B1 KR 102321172B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- antibody
- seq
- free
- disease
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Zoology (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217034984A KR102512797B1 (ko) | 2013-09-05 | 2014-09-05 | 염증성 질환에서 il-18 결합 단백질(il-18bp) |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13183193 | 2013-09-05 | ||
EP13183193.5 | 2013-09-05 | ||
PCT/EP2014/069013 WO2015032932A1 (en) | 2013-09-05 | 2014-09-05 | Il-18 binding protein (il-18bp) in inflammatory diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217034984A Division KR102512797B1 (ko) | 2013-09-05 | 2014-09-05 | 염증성 질환에서 il-18 결합 단백질(il-18bp) |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160044045A KR20160044045A (ko) | 2016-04-22 |
KR102321172B1 true KR102321172B1 (ko) | 2021-11-05 |
Family
ID=49111035
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217034984A KR102512797B1 (ko) | 2013-09-05 | 2014-09-05 | 염증성 질환에서 il-18 결합 단백질(il-18bp) |
KR1020167008846A KR102321172B1 (ko) | 2013-09-05 | 2014-09-05 | 염증성 질환에서 il-18 결합 단백질(il-18bp) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217034984A KR102512797B1 (ko) | 2013-09-05 | 2014-09-05 | 염증성 질환에서 il-18 결합 단백질(il-18bp) |
Country Status (25)
Country | Link |
---|---|
US (3) | US10858426B2 (el) |
EP (2) | EP3978526A1 (el) |
JP (2) | JP6820743B2 (el) |
KR (2) | KR102512797B1 (el) |
CN (2) | CN105722858A (el) |
AU (1) | AU2014317035B2 (el) |
CA (1) | CA2922498A1 (el) |
CL (1) | CL2016000506A1 (el) |
CY (1) | CY1124698T1 (el) |
DK (1) | DK3041864T3 (el) |
ES (1) | ES2892923T3 (el) |
HK (1) | HK1221726A1 (el) |
HU (1) | HUE055608T2 (el) |
IL (1) | IL244169B (el) |
LT (1) | LT3041864T (el) |
MX (1) | MX2016002719A (el) |
NZ (1) | NZ717671A (el) |
PH (1) | PH12016500425A1 (el) |
PL (1) | PL3041864T3 (el) |
PT (1) | PT3041864T (el) |
RU (1) | RU2731713C2 (el) |
SG (1) | SG11201601717VA (el) |
SI (1) | SI3041864T1 (el) |
UA (1) | UA125204C2 (el) |
WO (1) | WO2015032932A1 (el) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015032932A1 (en) | 2013-09-05 | 2015-03-12 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in inflammatory diseases |
MX2017010919A (es) * | 2015-03-05 | 2017-12-07 | Ab2 Bio Sa | Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. |
US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
GB201614455D0 (en) * | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
DE102016219607A1 (de) * | 2016-10-10 | 2018-04-12 | Siemens Healthcare Gmbh | Erzeugung einer mit anatomischen Bilddaten korrelierten Ergebniskarte |
WO2019133799A1 (en) * | 2017-12-29 | 2019-07-04 | University Of Florida Research Foundation | Monoclonal antibodies targeting microtubule-binding domain of tau protein |
TWI679279B (zh) * | 2018-05-09 | 2019-12-11 | 臺中榮民總醫院 | 檢測成人發作型史笛兒氏症之罹病風險及預後之方法 |
US20240262919A1 (en) * | 2018-06-19 | 2024-08-08 | Shanghaitech University | Human antibodies to human interleukin 18 receptor alpha and beta |
JP6892180B2 (ja) * | 2018-12-03 | 2021-06-23 | 株式会社mAbProtein | 活性型インターロイキン−18タンパク質のネオエピトープを認識する抗体、及びその応用 |
CN110433289A (zh) * | 2019-09-10 | 2019-11-12 | 中山大学附属口腔医院 | 用于治疗牙周致病菌感染引起的牙周膜细胞功能紊乱与牙槽骨丧失的药物 |
US20230173021A1 (en) | 2020-05-06 | 2023-06-08 | Ab2 Bio Sa | IL-18 Binding Protein (IL-18BP) In Respiratory Diseases |
GB202007404D0 (en) * | 2020-05-19 | 2020-07-01 | Nasser Syed Muhammad Tahir | Treatment for viral respiratory infections |
EP3943097A1 (en) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
KR20220044057A (ko) * | 2020-09-29 | 2022-04-06 | 주식회사 에이프릴바이오 | 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도 |
EP4371573A1 (en) | 2021-07-13 | 2024-05-22 | National University Corporation Tokai National Higher Education and Research System | Medicinal composition for treating inflammatory bowel disease |
WO2023067348A1 (en) * | 2021-10-21 | 2023-04-27 | Biosirius Ltd | Treatment for virally-induced pneumonia |
CN114236139A (zh) * | 2021-12-30 | 2022-03-25 | 苏州和锐生物科技有限公司 | 一种TNF-α生物制剂的抗体检测试剂盒、制备方法 |
WO2023166206A1 (en) | 2022-03-04 | 2023-09-07 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in the treatment of vexas |
WO2024148232A2 (en) | 2023-01-06 | 2024-07-11 | Alector Llc | Anti-il18 binding protein antibodies and methods of use thereof |
WO2024174994A1 (zh) * | 2023-02-20 | 2024-08-29 | 瑞石生物医药有限公司 | 抗IL-18Rβ抗体、其抗原结合片段及其医药应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
DK0567566T4 (da) | 1991-01-18 | 2007-10-22 | Amgen Inc | Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
US7129337B1 (en) | 1994-10-21 | 2006-10-31 | Innogenetics N.V. | Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents |
US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
TWI335336B (el) | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
DK1257292T3 (da) * | 2000-02-21 | 2011-07-18 | Merck Serono Sa | Anvendelse af IL-18-inhibitorer |
RS50926B (sr) | 2000-05-05 | 2010-08-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Upotreba il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze |
US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
CN1468250A (zh) | 2000-08-03 | 2004-01-14 | ��ķһ����˹��̹ | 在转基因动物中产生人源化抗体 |
AU2002224417A1 (en) | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
UA80676C2 (en) * | 2001-01-29 | 2007-10-25 | Applied Research Systems | Use of il-18 inhibitors for the treatment and/or prevention of cardiomyopathy |
DK1425028T3 (da) * | 2001-05-16 | 2010-03-01 | Yeda Res & Dev | Anvendelse af IL-18 inhibitorer til behandling eller forebyggelse af sepsis |
JP4344142B2 (ja) * | 2001-05-25 | 2009-10-14 | アレス トレーディング ソシエテ アノニム | Cns損傷の治療または予防のためのil−18阻害剤の使用 |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
SI1622939T1 (sl) * | 2003-05-13 | 2012-06-29 | Merck Serono Sa | Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
AU2011224023C1 (en) | 2003-11-12 | 2013-08-29 | Abbvie Inc. | IL-18 binding proteins |
JP4160615B2 (ja) | 2004-03-11 | 2008-10-01 | レドックス・バイオサイエンス株式会社 | プロテアーゼ阻害剤 |
EP1773403B1 (en) | 2004-07-09 | 2018-04-25 | The University of North Carolina At Chapel Hill | Alphavirus-based adjuvants |
MX2007002134A (es) | 2004-08-20 | 2007-09-14 | Smithkline Beecham Corp | Metodos para curar heridas administrando interleucina-18 humana. |
DK1885753T3 (da) | 2005-06-03 | 2011-10-03 | Ares Trading Sa | Fremstilling af rekombinant II-18-proteiner |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007030949A2 (en) | 2005-09-15 | 2007-03-22 | Val-Chum, S.E.C. | Methods of diagnosing ovarian cancer and kits therefor |
US20100028447A1 (en) | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
AU2008260572A1 (en) | 2007-05-29 | 2008-12-11 | Yale University | IL- 18 and protein kinase R inhibition for the treatment of COPD |
BR112013015508B1 (pt) * | 2010-12-20 | 2022-04-05 | Medimmune Limited | Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo |
JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
WO2015032932A1 (en) | 2013-09-05 | 2015-03-12 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in inflammatory diseases |
MX2017010919A (es) * | 2015-03-05 | 2017-12-07 | Ab2 Bio Sa | Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. |
-
2014
- 2014-09-05 WO PCT/EP2014/069013 patent/WO2015032932A1/en active Application Filing
- 2014-09-05 SI SI201431879T patent/SI3041864T1/sl unknown
- 2014-09-05 PT PT14759210T patent/PT3041864T/pt unknown
- 2014-09-05 KR KR1020217034984A patent/KR102512797B1/ko active IP Right Grant
- 2014-09-05 JP JP2016539564A patent/JP6820743B2/ja active Active
- 2014-09-05 NZ NZ717671A patent/NZ717671A/en unknown
- 2014-09-05 ES ES14759210T patent/ES2892923T3/es active Active
- 2014-09-05 UA UAA201603367A patent/UA125204C2/uk unknown
- 2014-09-05 KR KR1020167008846A patent/KR102321172B1/ko active IP Right Grant
- 2014-09-05 RU RU2016112596A patent/RU2731713C2/ru active
- 2014-09-05 MX MX2016002719A patent/MX2016002719A/es unknown
- 2014-09-05 CN CN201480060413.7A patent/CN105722858A/zh active Pending
- 2014-09-05 DK DK14759210.9T patent/DK3041864T3/da active
- 2014-09-05 EP EP21181013.0A patent/EP3978526A1/en active Pending
- 2014-09-05 HU HUE14759210A patent/HUE055608T2/hu unknown
- 2014-09-05 PL PL14759210T patent/PL3041864T3/pl unknown
- 2014-09-05 US US14/916,917 patent/US10858426B2/en active Active
- 2014-09-05 CA CA2922498A patent/CA2922498A1/en active Pending
- 2014-09-05 AU AU2014317035A patent/AU2014317035B2/en active Active
- 2014-09-05 EP EP14759210.9A patent/EP3041864B1/en active Active
- 2014-09-05 CN CN202210945119.0A patent/CN115925928A/zh active Pending
- 2014-09-05 LT LTEPPCT/EP2014/069013T patent/LT3041864T/lt unknown
- 2014-09-05 SG SG11201601717VA patent/SG11201601717VA/en unknown
-
2016
- 2016-02-17 IL IL244169A patent/IL244169B/en active IP Right Grant
- 2016-03-04 PH PH12016500425A patent/PH12016500425A1/en unknown
- 2016-03-04 CL CL2016000506A patent/CL2016000506A1/es unknown
- 2016-08-22 HK HK16109981.4A patent/HK1221726A1/zh unknown
-
2019
- 2019-11-21 JP JP2019210436A patent/JP2020055821A/ja active Pending
-
2020
- 2020-05-26 US US16/883,735 patent/US11530263B2/en active Active
-
2021
- 2021-09-16 CY CY20211100816T patent/CY1124698T1/el unknown
-
2022
- 2022-11-14 US US18/054,936 patent/US20230250164A1/en active Pending
Non-Patent Citations (1)
Title |
---|
J Autoimmun. 34(2):121-126(2010) |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102321172B1 (ko) | 염증성 질환에서 il-18 결합 단백질(il-18bp) | |
KR102511343B1 (ko) | 염증성 질환에서 il-18 결합 단백질(il-18bp) 및 항체 | |
US9394362B2 (en) | IL-21 antibodies and methods of making or using the antibodies | |
RU2810206C1 (ru) | Il-18-связывающий белок (il-18bp) и антитела при воспалительных заболеваниях | |
US20230416381A1 (en) | Methods for treating or preventing acute respiratory distress syndrome | |
WO2023166206A1 (en) | Il-18 binding protein (il-18bp) in the treatment of vexas | |
BR112016004772B1 (pt) | Método para determinação da quantidade de il-18 livre em uma amostra ou in situ, uso de um inibidor de il-18, e, kit de diagnóstico para detectar il-18 livre |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
A107 | Divisional application of patent | ||
GRNT | Written decision to grant |